Leflunomide Ratiopharm (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for de novo pyrimidine synthesis. By limiting pyrimidine production, the drug reduces the proliferation of activated lymphocytes, thereby dampening the autoimmune response that drives joint inflammation.

The dosing regimen for Leflunomide is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. The prescriber determines the appropriate starting dose, any loading dose, and subsequent maintenance dose.

Leflunomide is classified as pregnancy category X, meaning it is contraindicated during pregnancy because of proven teratogenic risk. It is also not recommended while breastfeeding, as it may be excreted in breast milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative to Leflunomide is methotrexate, another conventional DMARD. While both reduce disease activity, Leflunomide has a different safety profile, with less hepatic toxicity at low doses but a higher risk of hypertension and teratogenicity. Biologic agents are also alternatives for patients who do not respond adequately to conventional DMARDs.

Leflunomide tablets should be stored at ambient temperature, preferably below 25 °C. Keep the medication in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Leflunomide is taken orally, usually as a tablet swallowed whole with a glass of water. It can be taken with or without food, but patients should follow the specific instructions provided by their healthcare professional.

Serious risks include severe liver injury, life‑threatening skin reactions such as Stevens‑Johnson syndrome, bone‑marrow suppression leading to anemia or leukopenia, and interstitial lung disease. Patients should report any signs of jaundice, rash, unexplained fever, or respiratory symptoms promptly.

Leflunomide should not be used by pregnant women, women planning pregnancy, or those who are not using reliable contraception. It is also contraindicated in patients with severe liver disease, uncontrolled hypertension, or active serious infections, and caution is advised in those with a history of severe skin reactions.